Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
axitinib (inlyta) (1 trial)
bempegaldesleukin (1 trial)
dacomitinib (vizimpro) (1 trial)
gefitinib (iressa) (1 trial)
pembrolizumab (keytruda) (1 trial)
bentracimab (1 trial)
ticagrelor (brilinta) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Kidney Neoplasms (Phase 3)
Trials (4 total)
Trial APIs (7 total)